Prognostic role of integrin β1, E-cadherin, and rac1 expression in small cell lung cancer

被引:18
作者
Chang, Myung Hee [1 ,5 ]
Lee, Kyungji [2 ]
Lee, Kyo-Young [2 ]
Kim, Yeon Sil [3 ]
Kim, Young Kyoon [4 ]
Kang, Jin-Hyoung [1 ]
机构
[1] Catholic Univ, Div Oncol, Dept Med, Seoul St Marys Hosp,Sch Med, Seoul 137701, South Korea
[2] Catholic Univ, Dept Hosp Pathol, Sch Med, Seoul St Marys Hosp, Seoul 137701, South Korea
[3] Catholic Univ, Dept Radiat Oncol, Sch Med, Seoul St Marys Hosp, Seoul 137701, South Korea
[4] Catholic Univ, Div Pulmonol, Sch Med, Seoul St Marys Hosp,Dept Med, Seoul 137701, South Korea
[5] Ilsan Hosp, Div Hematooncol, Dept Med, Natl Hlth Insurance Corp, Koyang, South Korea
关键词
Small cell lung cancer; integrin ss 1; E-cadherin; rac1; RHO-GTPASES; PANCREATIC-CARCINOMA; CATENIN EXPRESSION; MEDIATED ADHESION; SURVIVAL; HYPERMETHYLATION; ACTIVATION; RECEPTORS; BINDING; IQGAP1;
D O I
10.1111/j.1600-0463.2011.02788.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Integrin beta(1) mediates cellular adhesion to the extracellular matrix (ECM) and is correlated with highly invasive and metastatic behavior in small cell lung cancer (SCLC). E-cadherin (ECAD) is a calcium-dependent cell-cell adhesion receptor that restricts invasion of cells and reduces metastasis. Rac1 is involved in the regulation of the actin cytoskeleton, adhesion, migration, invasion, and tumor metastasis. The aim of this study was to examine integrin beta(1), ECAD and rac1 expression in SCLC and to analyze the prognostic value of these markers in patients with SCLC. We analyzed integrin beta(1), ECAD, and rac1 expression in 112 SCLC tissues by immunohistochemical staining. Correlative analyses between integrin beta(1), ECAD, and rac1 expression and cliniopathological factors were performed. A total of 65 patients had extensive disease (ED) (58%), and 47 had limited disease (LD) (42%). The median follow-up duration was 61 months (range: 14-117 months), and the median progression free survival (PFS) and overall survival (OS) were 6.1 months (range: 4.8-7.4 months) and 9.7 months (range: 8.1-11.3 months), respectively. The expression of integrin beta(1), ECAD, and rac1 protein was observed in 64, 73, and 99 of SCLC tissues, respectively. The correlative analyses between integrin beta(1), ECAD, or rac1 expression and various clinical parameters did not show any statistical significance. However, the ECAD expression was associated with OS in the entire cohort. In contrast, the expression of integrin beta(1) and rac1 was not associated with PFS or OS. In a subgroup analysis, patients with less than two metastasis had significantly longer OS (p = 0.047) if their tumors expressed integrin beta(1) compared to those without integrin beta(1) expression. In addition, OS was longer for patients with ECAD positive tumors compared to those whose tumors did not express ECAD in males (p = 0.032) and patients who never smoked (p < 0.001). Multivariate analysis showed that LD (p = 0.004), overall response rate (p = 0.003), and expression of ECAD (p = 0.015) were the independent good prognostic factors for OS. LD (p = 0.024), overall response rate (p < 0.001), and less than two metastasis (p = 0.003) were prognostic factors for longer PFS. These results suggest that ECAD expression may be useful as a prognostic indicator in patients with SCLC.
引用
收藏
页码:28 / 38
页数:11
相关论文
共 50 条
  • [31] Study on the expression of E-cadherin in gastric cancer and lung cancer
    Liang, Jiawen
    Li, Lisu
    Fang, Zhou
    Zhang Anling
    Lei, Han
    Wang Bangmao
    Zhang Qingyu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 660 - 661
  • [32] Prognostic significance of E-cadherin and β-catenin in resected stage I non-small cell lung cancer
    Choi, YS
    Shim, YM
    Kim, SH
    Son, DS
    Lee, HS
    Kim, GY
    Han, J
    Kim, J
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2003, 24 (03) : 441 - 449
  • [33] Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression
    Jiang, Wei
    Fan, Hong
    Qian, Cheng
    Ding, Jianyong
    Wang, Qun
    Pang, Xuguang
    BMC CANCER, 2016, 16
  • [34] Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression
    Wei Jiang
    Hong Fan
    Cheng Qian
    Jianyong Ding
    Qun Wang
    Xuguang Pang
    BMC Cancer, 16
  • [35] Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer
    del Muro, XG
    Torregrosa, A
    Muñoz, J
    Castellsagué, X
    Condom, E
    Vigués, F
    Arance, A
    Fabra, A
    Germà, JR
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (03) : 357 - 362
  • [36] Elevated FUS/TLS expression is negatively associated with E-cadherin expression and prognosis of patients with non-small cell lung cancer
    Xiong, Dian
    Wu, Yong-Bing
    Jin, Chun
    Li, Ji-Jun
    Gu, Jie
    Liao, Yun-Fei
    Long, Xiang
    Zhu, Shu-Qiang
    Wu, Hai-Bo
    Xu, Jian-Jun
    Ding, Jian-Yong
    ONCOLOGY LETTERS, 2018, 16 (02) : 1791 - 1800
  • [37] Emerging roles of RAC1 in treating lung cancer patients
    Zou, T.
    Mao, X.
    Yin, J.
    Li, X.
    Chen, J.
    Zhu, T.
    Li, Q.
    Zhou, H.
    Liu, Z.
    CLINICAL GENETICS, 2017, 91 (04) : 520 - 528
  • [38] Prognostic Significance of E-Cadherin Protein Expression in Endometrial Cancer
    Vasilakaki, Th
    Tsavari, A.
    Skafida, E.
    Koulia, K.
    Moustou, E.
    Arkoumani, E.
    Myoteri, D.
    Manoloudaki, K.
    SCIENTIFIC CHRONICLES, 2012, 17 (02) : 83 - 86
  • [39] Prognostic Significance of Wnt-1, β-catenin and E-cadherin Expression in Advanced Colorectal Carcinoma
    Stanczak, Aleksandra
    Stec, Rafal
    Bodnar, Lubomir
    Olszewski, Wojciech
    Cichowicz, Marzena
    Kozlowski, Wojciech
    Szczylik, Cezary
    Pietrucha, Tadeusz
    Wieczorek, Maciej
    Lamparska-Przybysz, Monika
    PATHOLOGY & ONCOLOGY RESEARCH, 2011, 17 (04) : 955 - 963
  • [40] The role of Rac1 in the regulation of NFκB activity, cell proliferation and cell migration in non-small cell lung carcinoma
    Gastonguay, Adam J.
    Berg, Tracy J.
    Hauser, Andrew D.
    Schuld, Nathan J.
    Lorimer, Ellen L.
    Williams, Carol L.
    CANCER BIOLOGY & THERAPY, 2012, 13 (08) : 647 - 656